MGC Pharmaceuticals Limited
MGCLF · OTC
6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | |
|---|---|---|---|---|
| Revenue | $3,388 | $4,732 | $2,996 | $2,079 |
| % Growth | -28.4% | 57.9% | 44.1% | – |
| Cost of Goods Sold | $2,689 | $3,170 | $2,260 | $1,905 |
| Gross Profit | $1,286 | $1,562 | $736 | -$306 |
| % Margin | 38% | 33% | 24.6% | -14.7% |
| R&D Expenses | $1,993 | $2,718 | $5,860 | $5,370 |
| G&A Expenses | $13,860 | $9,302 | $7,220 | $3,746 |
| SG&A Expenses | $14,787 | $10,312 | $7,785 | $4,308 |
| Sales & Mktg Exp. | $927 | $1,009 | $565 | $562 |
| Other Operating Expenses | -$164 | -$166 | $828 | -$1,724 |
| Operating Expenses | $17,049 | $14,466 | $13,380 | $11,979 |
| Operating Income | -$15,493 | -$15,499 | -$11,939 | -$11,805 |
| % Margin | -457.3% | -327.5% | -398.5% | -567.8% |
| Other Income/Exp. Net | -$5,638 | -$5,269 | -$3,961 | -$7,484 |
| Pre-Tax Income | -$21,132 | -$20,768 | -$15,899 | -$18,770 |
| Tax Expense | $2 | -$420 | -$535 | -$429 |
| Net Income | -$20,824 | -$20,347 | -$15,870 | -$19,363 |
| % Margin | -614.6% | -430% | -529.7% | -931.4% |
| EPS | -7.1 | -7.9 | -8.3 | -14 |
| % Growth | 10.1% | 4.8% | 40.7% | – |
| EPS Diluted | -7.07 | -7.9 | -8.3 | -14 |
| Weighted Avg Shares Out | 2,947 | 2,566 | 1,906 | 1,382 |
| Weighted Avg Shares Out Dil | 2,947 | 2,566 | 1,906 | 1,382 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $8 | $12 |
| Interest Expense | $257 | $210 | $369 | $136 |
| Depreciation & Amortization | $752 | $494 | $643 | $491 |
| EBITDA | -$20,381 | -$15,160 | -$17,051 | -$18,662 |
| % Margin | -601.6% | -320.4% | -569.1% | -897.6% |